Context Therapeutics (NASDAQ:CNTX) Shares Down 7% – Here’s What Happened

Context Therapeutics Inc. (NASDAQ:CNTX) traded down 7% on Monday . The stock traded as low as $2.24 and last traded at $2.26. 991,291 shares traded hands during mid-day trading, an increase of 38% from the average session volume of 716,717 shares. The stock had previously closed at $2.43.

Wall Street Analyst Weigh In

A number of research firms recently commented on CNTX. D. Boral Capital reiterated a “buy” rating and set a $9.00 price target on shares of Context Therapeutics in a report on Tuesday, March 24th. Piper Sandler raised their price objective on shares of Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a research report on Monday. Wall Street Zen downgraded shares of Context Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th. Finally, Lifesci Capital upgraded shares of Context Therapeutics to a “strong-buy” rating in a research report on Monday, February 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $6.60.

Context Therapeutics Stock Up 1.7%

The company has a market cap of $221.43 million, a P/E ratio of -6.34 and a beta of 1.82. The firm’s 50 day moving average is $2.62 and its two-hundred day moving average is $1.83.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). As a group, research analysts forecast that Context Therapeutics Inc. will post -0.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CNTX. Virtu Financial LLC acquired a new position in Context Therapeutics in the fourth quarter valued at $43,000. Quadrature Capital Ltd acquired a new position in Context Therapeutics in the fourth quarter valued at $68,000. Clear Harbor Asset Management LLC lifted its holdings in Context Therapeutics by 60.5% in the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after buying an additional 35,000 shares during the period. Citadel Advisors LLC acquired a new position in Context Therapeutics in the third quarter valued at $100,000. Finally, XTX Topco Ltd lifted its holdings in Context Therapeutics by 858.8% in the fourth quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after buying an additional 91,008 shares during the period. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.